Surrozen (SRZN) Stock Price, News & Analysis

Company Overview

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Key Stats

• Today's Range: $9.95 to $10.28
• 50-Day Range: $6.55 to $10.64
• 52-Week Range: $4.50 to $16.19
• Volume: 11,717 shs
• Average Volume: 13,026 shs
• Market Capitalization: $32.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Surrozen Stock Analysis - MarketRank™

Surrozen scored higher than 35% of companies evaluated by MarketBeat, and ranked 812th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Surrozen.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Surrozen are expected to grow in the coming year, from ($9.49) to ($4.14) per share.

Price to Book Value per Share Ratio

Surrozen has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.10% of the float of Surrozen has been sold short.

Short Interest Ratio / Days to Cover

Surrozen has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Surrozen has recently increased by 0.61%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Surrozen does not currently pay a dividend.

Dividend Growth

Surrozen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.10% of the float of Surrozen has been sold short.

Short Interest Ratio / Days to Cover

Surrozen has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Surrozen has recently increased by 0.61%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.94

News Sentiment

Surrozen has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Surrozen this week, compared to 0 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Surrozen insiders have not sold or bought any company stock.

Percentage Held by Insiders

43.50% of the stock of Surrozen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.57% of the stock of Surrozen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SRZN Stock Analysis - Frequently Asked Questions

How have SRZN shares performed this year?

Surrozen's stock was trading at $9.40 at the beginning of the year. Since then, SRZN shares have increased by 9.0% and is now trading at $10.2499.
View the best growth stocks for 2024 here.

How were Surrozen's earnings last quarter?

Surrozen, Inc. (NASDAQ:SRZN) issued its quarterly earnings data on Monday, August, 12th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($2.79) by $1.25.

When did Surrozen's stock split?

Surrozen's stock reverse split before market open on Thursday, December 14th 2023. The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Surrozen's major shareholders?

Top institutional shareholders of Surrozen include Armistice Capital LLC (5.94%), Nantahala Capital Management LLC (5.85%), Stonepine Capital Management LLC (2.07%) and CVI Holdings LLC (2.03%).
View institutional ownership trends.

How do I buy shares of Surrozen?

Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/12/2024
• Today: 9/27/2024
• Next Earnings (Estimated): 11/13/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SRZN
• CUSIP: N/A
• CIK: 1824893
• Web: www.consonancehfw.com
• Phone: 650-489-9000
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-43,040,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -105.45%
• Return on Assets: -69.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.96
• Quick Ratio: 6.96

Sales & Book Value

• Annual Sales: $12.50 million
• Price / Sales: 2.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $18.39 per share
• Price / Book: 0.56

Miscellaneous

• Outstanding Shares: 3,199,000
• Free Float: 1,807,000
• Market Cap: $32.79 million
• Optionable: Not Optionable
• Beta: 0.93